<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145183</url>
  </required_header>
  <id_info>
    <org_study_id>P50DA018197-05</org_study_id>
    <secondary_id>P50DA018197-05</secondary_id>
    <secondary_id>P50DA018197</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT01145183</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics of Doxazosin for Cocaine Dependence</brief_title>
  <official_title>H-26605: Pharmacogenetics of Doxazosin for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doxazosin, an alpha 1-adrenergic receptor antagonist, may play an important role in cocaine
      addiction in humans. This study will evaluate to what extent the prospective screening for
      catecholamine related polymorphisms for alpha 1 NE receptor/transporter, COMT and DBH as main
      targets predict the treatment efficacy of doxazosin for cocaine-using behavior.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NE system, especially the alpha 1-adrenergic receptor, may play an important role in
      cocaine addiction in humans. The results of this study will provide medical safety data on
      the duration of the induction schedule that will be optimal for attaining our target dose of
      8 mg doxazosin daily and will guide future pharmacotherapy trials using Doxazosin or related
      alpha 1 receptor antagonists for cocaine addiction.

      This 16-week double-blind, placebo controlled clinical trial will provide treatment for 100
      cocaine-dependent patients and includes a 13 week medication trial (weeks 1-13) and up to 2
      week washout period(weeks 14-15). Qualifying subjects will be randomized to receive Doxazosin
      8 mg/day, or placebo during the study participation.

      Subjects will be receiving 1 mg study medication/placebo capsules at week 1, with 4mg/week
      induction rate for weeks, according to their randomized assignments, and are maintained on
      these agents through week 13. At the end of the study (weeks 14-15), participants will
      undergo discontinuation from active/placebo medication over a 2-week period. Subjects who
      wish to be transferred to an appropriate treatment program or treatment-research program will
      be helped with referral during the 2 week period (weeks 14-15).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Cocaine Positive Urine Toxicology</measure>
    <time_frame>2 weeks blocks throughout study</time_frame>
    <description>Cocaine positive urines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Pre- and post study medication</time_frame>
    <description>Adverse effects were closely monitored during each clinic visit throughout this trial. Vital signs including blood pressure (both pre-medication and post-medication) were measured and documented as were concomitant medications.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Doxazosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo daily dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.</description>
    <arm_group_label>Doxazosin</arm_group_label>
    <other_name>Cardura (Doxazosin Mesylate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo daily dosing</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugarpills ( Capsules)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (1) Signed informed consent form (2) Subject understands the risk and
        benefits and agrees to visit frequency and procedures (3) Male or female (4) Any race or
        ethnic origin (5)Diagnosis of cocaine-dependence according to DSM-IV criteria (6) between
        the ages of 18 and 64 (7)Must be current users of cocaine with self-reported use of cocaine
        at least once weekly for at least one month preceding study entry, cocaine-positive urine
        screen and score over 3 which is the cut-off for diagnosis of cocaine dependence as
        assessed with the Severity of Dependence Scale (Kaye &amp; Darke 2002; Gossop, et al 1995;
        Gossop, et al. 1997) (8)Women of childbearing age are eligible to be included in the study
        if they have a negative pregnancy test at screening, agree to adequate contraception to
        prevent pregnancy, to have monthly pregnancy tests, and they understand the risk of fetal
        toxicity due to medication.

        Exclusion Criteria: (1)Current diagnosis of other drug , especially alcohol or
        benzodiazepine dependence or abuse (other than cocaine or tobacco) (2) Significant medical
        conditions (e.g., major cardiovascular, renal, endocrine, hepatic disorders) such as
        abnormal liver function (with laboratory findings of SGOT or SGPT greater than three times
        normal), hypotension or hypertension, a current cardiac condition, and those having a high
        risk of cardiovascular disease, seizure disorders, or another significant underlying
        medical condition which would contraindicate Doxazosin treatment (3)Lifetime schizophrenia,
        bipolar disorder, or other psychotic disorders (4) Actively considering plans of
        suicidality or homicidality (5) Current use of a prescribed psychotropic medication that
        cannot be discontinued (6) Women planning to become pregnant or breastfeed during the
        study, or refuse to use a reliable form of birth control or refuse monthly pregnancy
        testing (7) Subjects who are prescribed any anti-hypertension drugs, except thiazides, will
        be excluded because these medications may interact with Doxazosin's brain effects in
        reducing cocaine abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R. Kosten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <results_first_submitted>September 20, 2018</results_first_submitted>
  <results_first_submitted_qc>July 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2019</results_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Thomas R. Kosten, MD</investigator_full_name>
    <investigator_title>Waggoner Chair and Professor of Psychiatry, Neuroscience, Pharmacology, Immunology and Pathology</investigator_title>
  </responsible_party>
  <keyword>Cocaine Dependence</keyword>
  <keyword>Substance Related Disorders</keyword>
  <keyword>genotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 201 individuals seeking treatment for cocaine dependence were screened between October 2009 and September 2013 at the Outpatient Clinical Trials Research Clinic at MEDVAMC. 16 participants were excluded because they did not meet the inclusion criteria, and 89 participants were lost to follow up before randomization into this study.</recruitment_details>
      <pre_assignment_details>Thus, 96 individuals entered into the study and were randomly assigned into the doxazosin or the placebo groups. Following randomization, 7 participants were lost to follow up and 13 opted out of the pharmacogenetic testing. In total, 76 CUD patients participated in this trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Doxazosin (AA Genotype)</title>
          <description>A single dose of doxazosin (8 mg/day) was used in the active medication arm with titration up to 8 mg occurring over a 2-week period.</description>
        </group>
        <group group_id="P2">
          <title>Doxazosin (AT/TT Genotype)</title>
          <description>A single dose of doxazosin (8 mg/day) was used in the active medication arm with titration up to 8 mg occurring over a 2-week period.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (AA Genotype)</title>
          <description>Matched placebo daily dosing</description>
        </group>
        <group group_id="P4">
          <title>Placebo (AT/TT Genotype)</title>
          <description>Matched placebo daily dosing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxazosin (AA Genotype)</title>
          <description>A single dose of doxazosin (8 mg/day) was used in the active medication arm with titration up to 8 mg occurring over a 2-week period.</description>
        </group>
        <group group_id="B2">
          <title>Doxazosin (AT/TT Genotype)</title>
          <description>A single dose of doxazosin (8 mg/day) was used in the active medication arm with titration up to 8 mg occurring over a 2-week period.</description>
        </group>
        <group group_id="B3">
          <title>Placebo (AA Genotype)</title>
          <description>Matched placebo daily dosing</description>
        </group>
        <group group_id="B4">
          <title>Placebo (AT/TT Genotype)</title>
          <description>Matched placebo daily dosing</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="6"/>
                    <measurement group_id="B2" value="48.9" spread="10.2"/>
                    <measurement group_id="B3" value="46.6" spread="9.2"/>
                    <measurement group_id="B4" value="48.8" spread="6"/>
                    <measurement group_id="B5" value="48" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Cocaine Positive Urine Toxicology</title>
        <description>Cocaine positive urines</description>
        <time_frame>2 weeks blocks throughout study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxazosin (AA Genotype)</title>
            <description>A single dose of doxazosin (8 mg/day) was used in the active medication arm with titration up to 8 mg occurring over a 2-week period.</description>
          </group>
          <group group_id="O2">
            <title>Doxazosin (AT/TT Genotype)</title>
            <description>A single dose of doxazosin (8 mg/day) was used in the active medication arm with titration up to 8 mg occurring over a 2-week period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (AA Genotype)</title>
            <description>Matched placebo daily dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo (AT/TT Genotype)</title>
            <description>Matched placebo daily dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Cocaine Positive Urine Toxicology</title>
          <description>Cocaine positive urines</description>
          <units>percentage of positive urines</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 1-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                    <measurement group_id="O2" value="85.6"/>
                    <measurement group_id="O3" value="75.7"/>
                    <measurement group_id="O4" value="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                    <measurement group_id="O2" value="84.7"/>
                    <measurement group_id="O3" value="82.8"/>
                    <measurement group_id="O4" value="84.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 5-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9"/>
                    <measurement group_id="O2" value="68.0"/>
                    <measurement group_id="O3" value="84.9"/>
                    <measurement group_id="O4" value="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 7-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5"/>
                    <measurement group_id="O2" value="70.3"/>
                    <measurement group_id="O3" value="77.2"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 9-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3"/>
                    <measurement group_id="O2" value="61.9"/>
                    <measurement group_id="O3" value="80.6"/>
                    <measurement group_id="O4" value="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 11-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8"/>
                    <measurement group_id="O2" value="67.3"/>
                    <measurement group_id="O3" value="81.2"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Adverse effects were closely monitored during each clinic visit throughout this trial. Vital signs including blood pressure (both pre-medication and post-medication) were measured and documented as were concomitant medications.</description>
        <time_frame>Pre- and post study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxazosin</title>
            <description>Doxazosin 8 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo daily dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Adverse effects were closely monitored during each clinic visit throughout this trial. Vital signs including blood pressure (both pre-medication and post-medication) were measured and documented as were concomitant medications.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Adverse effects were closely monitored during each clinic visit throughout this trial. Vital signs including blood pressure (both pre-medication and post-medication) were measured and documented as were concomitant medications.</desc>
      <group_list>
        <group group_id="E1">
          <title>Doxazosin</title>
          <description>Doxazosin 8 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched placebo daily dosing.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Kosten, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713 798 8628</phone>
      <email>kosten@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

